Red Clover for Cardiovascular and Cholesterol Health

Cardiovascular risk changes after menopause. Total and LDL cholesterol tend to rise, HDL often falls or shifts in quality, blood pressure creeps upward, body fat redistributes toward the abdomen, and the arteries themselves become measurably stiffer. Because estrogen influences all of these, it was reasonable to ask whether a plant estrogen might blunt some of the change.

Red clover has been tested for exactly that, and the results form an oddly shaped body of evidence. The cholesterol findings are modest, inconsistent and in several trials absent altogether. The findings on arterial stiffness — how flexible the large vessels are — are more reproducible and, in a way, more interesting, because they suggest the isoflavones do something real to blood vessels even when they leave the lipid panel untouched.

One boundary needs stating before anything else, and this page will repeat it. Every red clover cardiovascular study measures a surrogate marker: a number in a blood test or a machine reading. Not one has measured a heart attack, a stroke or a cardiovascular death. Whatever the markers show, nobody knows whether red clover changes anyone's actual cardiovascular outcome.

Table of Contents

  1. Why Cardiovascular Risk Rises After Menopause
  2. What Isoflavones Might Do to Blood Vessels
  3. Surrogate Markers and Their Limits
  4. The Cholesterol Trials
  5. The Lipid Meta-Analysis
  6. Arterial Stiffness and Compliance
  7. Blood Pressure
  8. Genotype, Equol and Individual Variation
  9. What Has Never Been Measured
  10. Practical Positioning
  11. Key Research Papers
  12. Safety and Disclaimer
  13. Connections

Why Cardiovascular Risk Rises After Menopause

Before menopause, women have lower rates of coronary heart disease than men of the same age. Afterwards the gap narrows steadily. Several changes cluster around the transition, and they are not all attributable to hormones — ageing runs alongside menopause and is itself the dominant cardiovascular risk factor.

What does shift around the transition includes: a rise in total and LDL cholesterol and in apolipoprotein B (the particle-count measure discussed on ApoB); a rise in triglycerides; changes in HDL that are more about function than quantity; a redistribution of body fat toward the abdomen with associated insulin resistance; a rise in blood pressure; and increased large-artery stiffness. Together these move a woman's lipid panel and overall risk profile in an unfavourable direction over a fairly short span of years.

Estrogen plausibly contributes to several of these through effects on hepatic lipoprotein handling, on the vascular endothelium's production of nitric oxide, and on vascular smooth muscle. That is the mechanistic opening a phytoestrogen was expected to exploit.

What Isoflavones Might Do to Blood Vessels

Red clover's isoflavones — biochanin A and formononetin, converted in the body to genistein and daidzein — have several proposed cardiovascular actions, all of them established in laboratory rather than clinical terms.

A plausible mechanism has never been sufficient reason to take anything. It is a reason to run a trial, and the trials were run.

Surrogate Markers and Their Limits

A surrogate marker stands in for an outcome that would take too long or too many participants to measure directly. LDL cholesterol is a well-validated surrogate — lowering it with statins reliably lowers cardiovascular events, so LDL earns its status. Arterial stiffness is a weaker surrogate: it predicts cardiovascular risk in observational studies, but it has not been established that changing it by any given means changes outcomes.

Cardiovascular medicine has learned this the hard way more than once. Interventions have raised HDL substantially without reducing events. Antiarrhythmic drugs suppressed the abnormal beats they targeted and increased mortality. The lesson is consistent: a favourable number is a hypothesis about benefit, not a benefit.

Red clover's cardiovascular evidence lives entirely in surrogate territory, and mostly in its weaker regions. That is not a reason to dismiss the findings — it is a reason to describe them accurately as what they are.

The Cholesterol Trials

The individual lipid trials do not point in one direction.

On the negative side, Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women (The Journal of Clinical Endocrinology and Metabolism, 1999) states its result in its title: the vessels changed, the lipids did not — find it on PubMed. Evidence tier: randomized clinical trial, null for lipids.

On the more encouraging side, The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia (Atherosclerosis, 2000) studied women who actually had raised cholesterol — a population with more room to improve than the healthy volunteers used elsewhere — find it on PubMed. The earlier The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism (Menopause, 2001) reported favourable movement including in HDL — find it on PubMed. Evidence tier: small randomized trials, positive.

Later trials continued the pattern of small and inconsistent effects. Influence of red clover-derived isoflavones on serum lipid profile in postmenopausal women (The Journal of Obstetrics and Gynaecology Research, 2009) is among the more favourable individual reports — find it on PubMed — and Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index (Gynecological Endocrinology, 2008) examined a higher-BMI population specifically — find it on PubMed. Evidence tier: randomized clinical trials, mixed.

Reading these together, the pattern is that where a lipid effect appears at all it is small, it is not the same lipid fraction each time, and it is more likely to show up in people whose lipids were abnormal to begin with. That is the signature of either a genuinely marginal effect or of chance findings scattered across many measured outcomes — and with several lipid fractions measured per trial, chance findings are expected.

The Lipid Meta-Analysis

The most useful single summary is Effects of red clover (Trifolium pratense) isoflavones on the lipid profile of menopausal women: a systematic review and meta-analysis (Journal of Clinical Medicine, 2020), which pooled the randomized lipid trials and found modest and inconsistent changes in parts of the cholesterol profile — some fractions moving favourably in pooled analysis, none dramatically, and with meaningful variation between studies — find it on PubMed. Evidence tier: systematic review of randomized trials.

Two things are worth holding onto from that. First, pooling did not reveal a strong hidden effect that individual trials had missed; it confirmed that the effect, if present, is small. Second, the heterogeneity between studies is itself informative — different extracts, doses, durations and populations producing different answers is exactly the situation in which a single pooled number should not be over-interpreted.

For comparison, and to keep the magnitude honest: statins typically lower LDL cholesterol by 30–50 percent and have randomized evidence that doing so prevents heart attacks. Nothing in the red clover literature is remotely in that range. The comparison is not meant to be dismissive — it is meant to prevent a small marker shift being read as a cardiovascular intervention.

Arterial Stiffness and Compliance

This is red clover's most reproducible cardiovascular finding, and the one that deserves genuine interest.

Arterial compliance describes how much the large arteries expand with each heartbeat; arterial stiffness is its inverse. Stiffer arteries raise systolic blood pressure, increase the workload on the left ventricle, and independently predict cardiovascular events in observational studies. Arteries stiffen with age, and the rate of stiffening appears to accelerate after menopause.

The 1999 study named above found that red clover isoflavones improved systemic arterial compliance in menopausal women even though plasma lipids were unchanged — a clean dissociation suggesting a direct vascular effect rather than a lipid-mediated one. Evidence tier: randomized clinical trial.

Supporting it, Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women (Arteriosclerosis, Thrombosis, and Vascular Biology, 2003) found the effect in both sexes — find it on PubMed. That it appears in men as well as postmenopausal women is a useful detail: it argues for a direct vascular action rather than something specific to estrogen-depleted physiology. Evidence tier: randomized clinical trial.

The honest caveat is the one from the surrogate-marker section. Arterial stiffness predicts risk; that does not establish that improving it by this particular means reduces risk. These trials were also short, and it is unknown whether any compliance improvement persists over years. The finding is real and worth following. It is not a demonstrated health benefit.

Blood Pressure

Blood pressure has been measured in several red clover trials, usually as a secondary outcome, and no consistent effect has emerged. Given the arterial-compliance findings a modest effect would not be surprising, but the trials were not designed or powered to detect one, and secondary outcomes across small studies are exactly where spurious results accumulate.

The current honest statement is that red clover has not been shown to lower blood pressure, and nobody with hypertension should treat it as part of their management. The interested reader can review the accumulated evidence via a PubMed topic search on red clover isoflavones and blood pressure. Established approaches to blood pressure are covered under Hypertension. Evidence tier: insufficient.

Genotype, Equol and Individual Variation

One red clover trial did something unusual and useful: it looked at whether the response depended on who was taking it. Modest protective effects of isoflavones from a red clover-derived dietary supplement on cardiovascular disease risk factors in perimenopausal women, and evidence of an interaction with ApoE genotype in 49–65 year-old women (The Journal of Nutrition, 2004) reported both a modest overall effect and an apparent interaction with ApoE genotype, a well-known genetic determinant of lipid metabolism — find it on PubMed. Evidence tier: randomized trial with exploratory subgroup analysis.

Subgroup findings require caution — they are a classic source of results that fail to replicate — but the idea is consistent with the second source of variation running through this whole topic: equol producer status. As described on the menopause page, only a minority of people carry gut bacteria that convert daidzein into the more active metabolite equol, and Equol: history, chemistry, and formation (The Journal of Nutrition, 2010) sets out the chemistry — find it on PubMed.

If both genotype and microbiome modify the response, then a trial averaging across a mixed population would systematically understate the effect in responders and overstate it in everyone else. That is a coherent explanation for a literature full of small, inconsistent results. It is also, at present, untested as a clinical strategy — no one is going to genotype you before selling you clover capsules.

What Has Never Been Measured

This section is short because the list is short and the point is important.

No red clover trial has measured a heart attack, a stroke, a cardiovascular death, or all-cause mortality. Not one. The trials are weeks to months long and enrol dozens to a few hundred people; detecting an effect on events would require thousands of participants followed for years, and that study has never been funded or attempted.

This is not a criticism of the researchers, who did what was feasible. It is a limit on what anyone may claim. Statements that red clover "supports heart health" are extrapolations from small surrogate-marker changes, not conclusions from outcome data. Nobody knows whether taking red clover for a decade makes a cardiovascular event more likely, less likely, or neither.

Practical Positioning

Where does that leave a reader with a cholesterol result they are unhappy about, or a family history that worries them?

Red clover is not a cardiovascular treatment. It should not replace, delay or reduce anything a clinician has recommended, and it should not be the plan for elevated cholesterol or blood pressure. If someone is already taking it for menopausal symptoms, any cardiovascular effect is a possible small bonus of unknown clinical value — not a second reason to take it.

The interventions with real evidence are unglamorous and well known: not smoking; regular physical activity; a dietary pattern built on whole foods, vegetables, fruit, nuts, fish, olive oil and whole grains such as brown rice; managing blood pressure; managing blood sugar; and, where risk warrants it, lipid-lowering medication with randomized outcome evidence behind it. Those are covered under Cholesterol Management, Atherosclerosis and Cardiovascular Disease.

Knowing your actual numbers matters more than any supplement decision. A lipid panel, and increasingly ApoB, plus hs-CRP where inflammation is a question, will tell you far more than a bottle will.

One safety point specific to this topic: red clover contains coumarin-type compounds and carries a theoretical interaction with anticoagulant and antiplatelet medication. Since many people with cardiovascular disease are taking exactly those drugs, this caution applies disproportionately to the readers most likely to be interested in this page. See Isoflavones, Hormones and Safety and the PT/INR page.

Key Research Papers

  1. Effects of red clover (Trifolium pratense) isoflavones on the lipid profile of menopausal women: a systematic review and meta-analysis — Journal of Clinical Medicine, 2020. Find on PubMed
  2. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women — The Journal of Clinical Endocrinology and Metabolism, 1999. Find on PubMed
  3. Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women — Arteriosclerosis, Thrombosis, and Vascular Biology, 2003. Find on PubMed
  4. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia — Atherosclerosis, 2000. Find on PubMed
  5. Modest protective effects of isoflavones from a red clover-derived dietary supplement on cardiovascular disease risk factors in perimenopausal women, and evidence of an interaction with ApoE genotype in 49–65 year-old women — The Journal of Nutrition, 2004. Find on PubMed
  6. Influence of red clover-derived isoflavones on serum lipid profile in postmenopausal women — The Journal of Obstetrics and Gynaecology Research, 2009. Find on PubMed
  7. Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index — Gynecological Endocrinology, 2008. Find on PubMed
  8. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism — Menopause, 2001. Find on PubMed
  9. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? — The Journal of Steroid Biochemistry and Molecular Biology, 2005. Find on PubMed
  10. Equol: history, chemistry, and formation — The Journal of Nutrition, 2010. Find on PubMed
  11. PubMed topic search: Trifolium pratense isoflavones blood pressure randomized. Run this search
  12. PubMed topic search: Trifolium pratense endothelial function flow-mediated dilation. Run this search

Back to Table of Contents

Safety and Disclaimer

Red clover contains coumarin-type compounds and carries a theoretical interaction with anticoagulant and antiplatelet medication such as warfarin, aspirin and clopidogrel — a caution that matters especially for readers with cardiovascular disease, since many are already taking those drugs. It is a phytoestrogen, so it should be avoided in pregnancy and breastfeeding and used only after medical advice by anyone with a history of breast, uterine or ovarian cancer, endometriosis or uterine fibroids, or anyone taking hormone therapy, tamoxifen or an aromatase inhibitor. It is commonly advised to stop it about two weeks before scheduled surgery. Full detail is on Red Clover Isoflavones, Hormones and Safety. Red clover is not a treatment for high cholesterol, high blood pressure or heart disease, and nothing on this page should delay or replace medical care. This is educational information, not medical advice.

Connections

Back to Table of Contents